invasive fungal infection prophylaxis
Infectious disease · 2008–2014
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| voriconazole Prophylaxis of invasive fungal infections, including yeasts and moulds, in patients at high risk of developing such infections (specifically in AML/MDS… | Mar 2014 | Recommended with restriction | none received |
| posaconazole Prophylaxis of invasive fungal infections (yeasts and moulds) in patients 13 years of age or older at high risk, including those with neutropenia or graft… | Mar 2008 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.